Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke (ECASS-3)
Source: View publication →
The ECASS-3 trial demonstrated that intravenous alteplase administered between 3 and 4.5 hours after the onset of acute ischemic stroke symptoms significantly improved functional outcomes at 90 days compared to placebo, despite an increased risk of symptomatic intracranial hemorrhage.
Key Findings
Study Design
Study Limitations
Clinical Significance
The results of the ECASS-3 trial were instrumental in expanding the approved therapeutic window for intravenous thrombolysis in acute ischemic stroke from 3 hours to 4.5 hours, allowing a broader population of patients to receive evidence-based reperfusion therapy.
Historical Context
Prior to this study, the landmark 1995 NINDS trial established intravenous alteplase as the standard of care only for patients treated within 3 hours of symptom onset. Subsequent pooled analyses and the ECASS-3 trial provided the necessary prospective randomized data to safely extend this treatment window.
Guided Discussion
High-yield insights from every perspective
What is the biochemical mechanism of action of alteplase (rt-PA) in the treatment of acute ischemic stroke, and why does the benefit of this therapy rapidly diminish as the time from symptom onset increases?
Key Response
Alteplase is a recombinant tissue plasminogen activator that binds to fibrin in a thrombus and converts trapped plasminogen to plasmin, which then initiates local fibrinolysis. The 'time is brain' concept is rooted in the pathophysiology of the ischemic penumbra; as time passes, the salvageable brain tissue progresses to irreversible infarction, and the risk of reperfusion injury and hemorrhagic transformation increases due to blood-brain barrier degradation.
The ECASS-3 trial extended the thrombolysis window to 4.5 hours, but utilized more stringent exclusion criteria than the original 0-3 hour NINDS trial. Which specific patient subgroups were excluded from the 3-4.5 hour window in ECASS-3 that are often eligible in the <3-hour window?
Key Response
ECASS-3 excluded patients older than 80 years, those with a combination of prior stroke and diabetes mellitus, those taking any oral anticoagulants (regardless of INR), and those with a baseline NIH Stroke Scale score >25. While some of these are now managed more flexibly in clinical practice, they represent the specific trial-based safety constraints for the extended window.
In ECASS-3, the rate of symptomatic intracranial hemorrhage (sICH) was significantly higher in the alteplase group compared to placebo (2.4% vs 0.2% per the ECASS definition). How does the definition of sICH used in this trial compare to the SITS-MOST or NINDS definitions, and how does this affect the interpretation of safety across different stroke trials?
Key Response
ECASS-3 defined sICH as blood on imaging plus an increase in NIHSS of 4 points or more, or if the hemorrhage led to death. The definition used greatly impacts reported rates; for instance, the NINDS definition is broader (any neurological decline plus any blood), typically yielding higher ICH rates. Fellows must recognize that 'safety' is definition-dependent when comparing alteplase, tenecteplase, or endovascular trials.
Given that the Number Needed to Treat (NNT) for a favorable outcome (mRS 0-1) increases from approximately 4-5 in the 0-3 hour window to 14 in the 3-4.5 hour window, how should this evidence influence your bedside 'teaching' and 'process' regarding 'door-to-needle' targets?
Key Response
The attending must emphasize that while ECASS-3 provides a 'safety net' for late arrivals, it should not justify a lack of urgency. The efficacy of alteplase is highly time-dependent; earlier treatment results in significantly better outcomes. Clinical processes should still target <60 (or <45) minute door-to-needle times regardless of whether the patient arrives at 1 hour or 3.5 hours.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
Analyze the potential impact of baseline imbalances in the ECASS-3 trial, specifically the slightly higher baseline NIHSS and higher prevalence of previous stroke in the placebo group. To what extent might these imbalances have inflated the perceived efficacy of alteplase in the primary endpoint analysis?
Key Response
Although the differences were small, baseline stroke severity is the most powerful predictor of outcome. If the placebo group was slightly 'sicker' at baseline, the treatment effect of alteplase might be over-estimated. A PhD-level critique would focus on the sensitivity analyses and adjusted odds ratios provided by the authors to determine if the 1.34 OR for favorable outcome remains robust after controlling for these prognostic variables.
If you were the lead reviewer for the ECASS-3 manuscript, how would you address the discrepancy between the significant improvement in the primary endpoint (mRS 0-1) and the lack of significant difference in mortality (7.7% vs 8.4%) despite the increased rate of sICH?
Key Response
A critical reviewer would flag that while alteplase improves functional independence, it does not necessarily improve survival. The editor would ensure the authors do not overstate the benefit as a 'survival' benefit and would require a transparent discussion on the trade-off: a higher chance of a 'perfect' recovery balanced against the risk of an iatrogenic, potentially fatal hemorrhage.
The AHA/ASA guidelines currently recommend intravenous alteplase in the 3-4.5 hour window with a Class I, Level of Evidence B-R. Why is the level of evidence lower than the 0-3 hour window (Level A), and what specific data would be needed to harmonize these recommendations?
Key Response
The 0-3 hour window is supported by multiple large-scale RCTs (NINDS, ECASS-1, ECASS-2, ATLANTIS), whereas the 3-4.5 hour window relies heavily on ECASS-3 and meta-analyses. To reach Level A, more randomized data or larger registry-based evidence confirming the results in the general population (especially those excluded in ECASS-3, like the elderly) was historically required. Current guidelines emphasize that while effective, the evidence base is narrower for the extended window.
Clinical Landscape
Noteworthy Related Trials
NINDS rt-PA Stroke Study
Tested
Intravenous rt-PA (alteplase)
Population
Patients with acute ischemic stroke within 3 hours of onset
Comparator
Placebo
Endpoint
Favorable outcome at 3 months (Barthel index, modified Rankin scale, Glasgow outcome scale, NIHSS)
ECASS-I
Tested
Intravenous alteplase
Population
Patients with acute ischemic stroke within 6 hours of onset
Comparator
Placebo
Endpoint
Neurological improvement at 90 days
ATLANTIS Trial
Tested
Intravenous alteplase
Population
Patients with acute ischemic stroke within 3 to 5 hours of onset
Comparator
Placebo
Endpoint
Excellent neurological recovery at 90 days (NIHSS score 0-1)
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis